Reported about 13 hours ago
Eli Lilly's preliminary 2024 revenue is expected to reach $45 billion, falling below analysts' projections of $45.5 billion due to lower sales of its weight loss and diabetes injections. Despite this setback, experts suggest that the promising GLP-1 oral treatment on the horizon could significantly boost the company's stock value moving forward.
Source: YAHOO